Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

NCT ID: NCT07122713Sponsor: Alexander StessinLast updated: 2025-12-17

Summary

The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.

Detailed description

Patients who cannot undergo surgical resection for either breast cancer or local control of metastatic cancer have limited effective treatment options. Treatments typically employed in the adjuvant setting have been found in the definitive setting to be inferior to surgery followed by adjuvant therapy. This raises the necessity of evaluating the use of ablative doses of radiation to provide durable local control of the tumor in such patients. Indeed, there is growing evidence that RT is effective in the adjuvant setting. This is a study of concurrent ultra-hypofractionated whole breast whole breast radiation delivered via simultaneous integrated boost to the gross tumor for breast cancer patients not undergoing surgery.

Arms & interventions

  • RadiationWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor

    Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions

  • RadiationWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes

    Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions

Outcome measures

Primary

  • Treatment Safety

    Incidence of physician-assessed treatment-related toxicity ≥ Grade 4 events, as defined using CTCAE 5.0

    Time frame: 12 months

Secondary

  • Acute Toxicity

    Time frame: 12 months

  • Late Toxicity

    Time frame: 5 years

  • Treatment Tolerability by EORTC QLQ-C30

    Time frame: 2 years

  • Treatment Tolerability by EORTC QLQ-BR42

    Time frame: 2 years

  • Tumor Response Rate in the Gross Disease Volume (40Gy)

    Time frame: 1 year

  • Progression Free Rate in the Microscopic Disease Volume (26Gy)

    Time frame: 1 year

  • Clinical Response in patients with Palpable Disease

    Time frame: 1 year

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Biopsy proven invasive carcinoma of the breast, either lobular, ductal and/or no special type * T1-T4, N0-2, M0-1 invasive breast carcinoma by radiological or clinical criteria * Cancer is deemed unresectable, or the patient is a poor surgical candidate as determined following evaluation by a surgeon, or patient declines surgery. * Life expectancy \> 6 months * Negative pregnancy test at the time of start of treatment in any female of reproductive age Exclusion Criteria: * Concurrent systemic therapy (except for endocrine therapy, HER2-targeted therapy, or immunotherapy which are permitted) * Prior radiation to ipsilateral breast or regional nodes * Inability to receive study treatment planning and treatment secondary to body habitus

Study locations (1)

Stony Brook University Cancer Center

Stony Brook, New York, 11794

Recruiting
Cancer Clinical Trials Office · Contact
Alexander Stessin, MD PhD · Principal Investigator